$28.87
Insights on Supernus Pharmaceuticals Inc
Revenue is up for the last 3 quarters, 135.56M → 164.31M (in $), with an average increase of 9.1% per quarter
Netprofit is up for the last 2 quarters, -15.97M → 1.17M (in $), with an average increase of 1459.7% per quarter
In the last 1 year, Catalent, Inc. has given 33.0% return, outperforming this stock by 53.1%
0.83%
Downside
Day's Volatility :2.88%
Upside
2.07%
23.83%
Downside
52 Weeks Volatility :43.75%
Upside
26.14%
Period | Supernus Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 5.38% | -0.7% | 0.0% |
6 Months | 14.94% | 6.6% | 0.0% |
1 Year | -20.07% | 3.7% | -1.5% |
3 Years | -6.3% | 14.0% | -21.8% |
Market Capitalization | 1.6B |
Book Value | $16.84 |
Earnings Per Share (EPS) | 0.02 |
PE Ratio | 1471.5 |
PEG Ratio | 1.47 |
Wall Street Target Price | 40.5 |
Profit Margin | 0.22% |
Operating Margin TTM | 11.56% |
Return On Assets TTM | 0.56% |
Return On Equity TTM | 0.15% |
Revenue TTM | 607.5M |
Revenue Per Share TTM | 11.14 |
Quarterly Revenue Growth YOY | -1.7999999999999998% |
Gross Profit TTM | 580.0M |
EBITDA | 98.3M |
Diluted Eps TTM | 0.02 |
Quarterly Earnings Growth YOY | -0.96 |
EPS Estimate Current Year | 1.64 |
EPS Estimate Next Year | 1.95 |
EPS Estimate Current Quarter | 0.55 |
EPS Estimate Next Quarter | 0.38 |
What analysts predicted
Upside of 40.28%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 408.9M | ↑ 35.29% |
Net Income | 111.0M | ↑ 93.76% |
Net Profit Margin | 27.14% | ↑ 8.19% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 392.8M | ↓ 3.95% |
Net Income | 113.1M | ↑ 1.86% |
Net Profit Margin | 28.79% | ↑ 1.65% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 520.4M | ↑ 32.5% |
Net Income | 127.0M | ↑ 12.29% |
Net Profit Margin | 24.39% | ↓ 4.4% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 579.8M | ↑ 11.41% |
Net Income | 53.4M | ↓ 57.92% |
Net Profit Margin | 9.21% | ↓ 15.18% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 667.2M | ↑ 15.09% |
Net Income | 60.7M | ↑ 13.64% |
Net Profit Margin | 9.1% | ↓ 0.11% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 607.5M | ↓ 8.95% |
Net Income | 1.3M | ↓ 97.83% |
Net Profit Margin | 0.22% | ↓ 8.88% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 177.4M | ↑ 4.29% |
Net Income | 1.7M | ↓ 77.76% |
Net Profit Margin | 0.99% | ↓ 3.64% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 167.3M | ↓ 5.65% |
Net Income | 25.5M | ↑ 1356.89% |
Net Profit Margin | 15.23% | ↑ 14.24% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 153.8M | ↓ 8.11% |
Net Income | 16.9M | ↓ 33.49% |
Net Profit Margin | 11.02% | ↓ 4.21% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 135.6M | ↓ 11.84% |
Net Income | -831.0K | ↓ 104.9% |
Net Profit Margin | -0.61% | ↓ 11.63% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 153.9M | ↑ 13.51% |
Net Income | -16.0M | ↑ 1822.5% |
Net Profit Margin | -10.38% | ↓ 9.77% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 164.3M | ↑ 6.78% |
Net Income | 1.2M | ↓ 107.35% |
Net Profit Margin | 0.72% | ↑ 11.1% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 977.8M | ↑ 130.36% |
Total Liabilities | 524.8M | ↑ 234.29% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 18.66% |
Total Liabilities | 564.9M | ↑ 7.63% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↑ 29.63% |
Total Liabilities | 759.2M | ↑ 34.41% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 12.3% |
Total Liabilities | 873.3M | ↑ 15.02% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 0.79% |
Total Liabilities | 816.3M | ↓ 6.53% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↓ 17.24% |
Total Liabilities | 487.5M | ↓ 40.28% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 0.11% |
Total Liabilities | 840.3M | ↓ 1.55% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↑ 0.55% |
Total Liabilities | 816.3M | ↓ 2.86% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↑ 5.25% |
Total Liabilities | 879.7M | ↑ 7.76% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 27.83% |
Total Liabilities | 373.2M | ↓ 57.58% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 0.61% |
Total Liabilities | 373.0M | ↓ 0.06% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 9.63% |
Total Liabilities | 487.5M | ↑ 30.7% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 129.0M | ↑ 12.51% |
Investing Cash Flow | -413.5M | ↑ 378.48% |
Financing Cash Flow | 376.4M | ↑ 6526.26% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 143.1M | ↑ 10.96% |
Investing Cash Flow | -157.9M | ↓ 61.81% |
Financing Cash Flow | 3.9M | ↓ 98.96% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 138.4M | ↓ 3.3% |
Investing Cash Flow | -34.7M | ↓ 78.03% |
Financing Cash Flow | 3.6M | ↓ 9.39% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 127.1M | ↓ 8.14% |
Investing Cash Flow | -81.9M | ↑ 136.07% |
Financing Cash Flow | -130.4M | ↓ 3764.51% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 116.8M | ↓ 8.1% |
Investing Cash Flow | -216.7M | ↑ 164.5% |
Financing Cash Flow | -10.5M | ↓ 91.97% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 13.8M | ↓ 80.54% |
Investing Cash Flow | -82.2M | ↑ 424.47% |
Financing Cash Flow | 6.5M | ↑ 183.99% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 27.6M | ↑ 99.15% |
Investing Cash Flow | -48.8M | ↓ 40.7% |
Financing Cash Flow | 2.8M | ↓ 56.17% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 49.1M | ↑ 78.23% |
Investing Cash Flow | 239.8M | ↓ 591.71% |
Financing Cash Flow | 80.2M | ↑ 2734.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -18.9M | ↓ 138.42% |
Investing Cash Flow | 60.3M | ↓ 74.85% |
Financing Cash Flow | -478.9M | ↓ 697.35% |
Sell
Neutral
Buy
Supernus Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Supernus Pharmaceuticals Inc | -15.18% | 14.94% | -20.07% | -6.3% | -19.6% |
Neurocrine Biosciences Inc. | -4.45% | 18.72% | 28.45% | 40.46% | 69.87% |
Haleon Plc Spon Ads | -0.12% | -1.82% | -7.31% | 9.45% | 9.45% |
Zoetis Inc. | -10.98% | -10.38% | -12.9% | -9.61% | 53.43% |
Viatris Inc. | -5.61% | 18.46% | 12.35% | -16.23% | -32.07% |
Catalent, Inc. | 0.0% | 24.33% | 32.98% | -48.49% | 27.27% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Supernus Pharmaceuticals Inc | 1471.5 | 1471.5 | 1.47 | 1.64 | 0.0 | 0.01 | NA | 16.84 |
Neurocrine Biosciences Inc. | 53.84 | 53.84 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 28.93 | 28.93 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 29.48 | 29.48 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 222.4 | 222.4 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Supernus Pharmaceuticals Inc | Buy | $1.6B | -19.6% | 1471.5 | 0.22% |
Neurocrine Biosciences Inc. | Buy | $13.4B | 69.87% | 53.84 | 13.23% |
Haleon Plc Spon Ads | Buy | $37.0B | 9.45% | 28.93 | 9.28% |
Zoetis Inc. | Buy | $68.5B | 53.43% | 29.48 | 27.43% |
Viatris Inc. | Hold | $13.2B | -32.07% | 222.4 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 27.27% | 211.02 | -31.77% |
BlackRock Inc
Vanguard Group Inc
Armistice Capital, LLC
Macquarie Group Ltd
Dimensional Fund Advisors, Inc.
State Street Corporation
pioneering new medicines in neurology and psychiatry with more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (cns) disorders. in 2013 we launched oxtellar xr® and trokendi xr®, two novel neurology products for the treatment of epilepsy. we are also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder (adhd) and its coexisting disorders, and depression. we are developing differentiated products by leveraging our proprietary and in-licensed technologies. we use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
Organization | Supernus Pharmaceuticals Inc |
Employees | 652 |
CEO | Mr. Jack A. Khattar |
Industry | Health Technology |